Bladder cancer (bladder cancer) is the tenth most common cancer in the world, ranking 13th in
the number of deaths. There are about 549000 new cases of bladder cancer worldwide, with
200000 deaths and a higher incidence rate in men than in women. In 2013, the incidence rate
of bladder cancer was high in China, accounting for 2.02% of all new cases. Bladder cancer
has become a major disease threatening people's life and health. Therefore, the exploration
of the mechanism of the occurrence and development of bladder cancer and effective drugs has
been an important focus of bladder cancer research. The current treatment of bladder cancer
is mainly TURBT (transurethral resection of bladder tumour) resection and BCG, chemotherapy
adjuvant treatment, but its recurrence and metastasis still exist, so this study aims to
explore an effective drug treatment. The purpose of this study was to investigate the safety
and efficacy of propranolol in adjuvant BCG therapy, and whether propranolol can effectively
alleviate the metastasis and recurrence of bladder cancer and improve the survival time after
bladder cancer surgery.